AUROBINDO

Date: December 16, 2016

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sirs,

Sub: Clarification / Confirmation on news item appeared in "Economic Times"

With reference to your mail dated 16th December, 2016, with regard to the news item which appeared in Economic Times on December 16, 2016, we wish to state as under:

a) Aurobindo received a subpoena in Mar 2016 requesting non-product specific information. We have cooperated with the Department of Justice and provided documents pursuant to that.
b) We have not received any further requests for information pursuant to that Mar 2016 subpoena, nor we have received any further subpoenas.
c) On December 15, 2016 Aurobindo became aware of the compliant from numerous States filed in Connecticut.
d) The sales of the referred product i.e Glyburide by our US subsidiary is not material as it is around USD 1.1 million in FY 2016 as per the IMS data.
e) Aurobindo will cooperate with all appropriate authorities in this regard.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Re.

B ADI REDDY
COMPANY SECRETARY

AUROBINDO PHARMA LTD. HYD.